Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less ... more

• Daily Updates: Oncology - Tracking breaking research, drug development news & new trials

  EURO€ 88.00USD$ 82.00GBP£ 50.00AUD$ 120.00JPY¥ 10,092.00SEK 710,00CHF 118.00CAD$ 110.00 Lead Discovery, May 2013
  DailyUpdates was launched in 2002 by the pharmaceutical analysts Lead Discovery to provide the R&D sector with a unique intelligence tool We use proprietary search engine technology to identify breaking...

• Future Oncology

  EURO€ 3,734.00USD$ 3,490.00GBP£ 2,122.00AUD$ 5,081.00JPY¥ 428,245.00SEK 30 115,00CHF 5'012.00CAD$ 4,665.00 New MEdicine Inc, May 2013
  Future Oncology is an analytical newsletter for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care industries It provides comprehensive,...

• Cancer Imaging - The Official Publication of the International Cancer Imaging Society

  EURO€ 36.00USD$ 47.00GBP£ 30.00AUD$ 46.00JPY¥ 4,624.00SEK 308,00CHF 44.00CAD$ 48.00 e-MED Ltd, May 2013 , Pages +: 400
  Cancer Imaging - The Official Journal of the International Cancer Imaging Society Cancer Imaging selected for coverage in Science Citation Index Expanded: Impact Factor due 2011 Cancer Imaging is now...

• Oncology Pipeline Database

  EURO€ 1,800.00USD$ 2,342.00GBP£ 1,514.00AUD$ 2,290.00JPY¥ 231,208.00SEK 15 376,00CHF 2'207.00CAD$ 2,386.00 La Merie Publishing, May 2013
  Subscription "Oncology Pipeline Database" provides online access to more than 3,000 project entries in oncology Each project is specified for its Target or Mechanism of Action, Product Category and...

• Oncology Media Monitor

  EURO€ 1,842.00USD$ 2,397.00GBP£ 1,550.00AUD$ 2,344.00JPY¥ 236,645.00SEK 15 737,00CHF 2'259.00CAD$ 2,442.00 Moreover Technologies, May 2013
  About the service: When oncology news breaks, we get it fast—so you can deliver fresh business intelligence - Search 33,500 news sources - Plus, search 508,000 social media sources - Covers 200 countries...

• Daily Updates: Cancer Immunotherapy - Tracking breaking research, drug development news new trials

  EURO€ 88.00USD$ 82.00GBP£ 50.00AUD$ 120.00JPY¥ 10,092.00SEK 710,00CHF 118.00CAD$ 110.00 Lead Discovery, May 2013
  DailyUpdates was launched in 2002 by the pharmaceutical analysts Lead Discovery to provide the R&D sector with a unique intelligence tool We use proprietary search engine technology to identify breaking...

• Triple Target Atlas in Oncology Drug Development

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, May 2013
  With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming...

• Hematology

  EURO€ 229.00USD$ 298.00GBP£ 193.00AUD$ 292.00JPY¥ 29,466.00SEK 1 960,00CHF 281.00CAD$ 304.00 Maney Publishing, May 2013
  6 issues per year Hematology is an international journal, publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology...

• Journal of Chemotherapy

  EURO€ 144.00USD$ 187.00GBP£ 121.00AUD$ 183.00JPY¥ 18,474.00SEK 1 229,00CHF 176.00CAD$ 191.00 Maney Publishing, May 2013
  The Journal of Chemotherapy is an international scholarly journal published bimonthly under the auspices of the Italian Society of Chemotherapy and of the Italian Federation of Human and Animal Mycopathology...

• Cancer Diagnostic Testing World Markets

  EURO€ 2,613.00USD$ 3,400.00GBP£ 2,199.00AUD$ 3,325.00JPY¥ 335,692.00SEK 22 324,00CHF 3'205.00CAD$ 3,465.00 TriMark Publications, May 2013 , Pages: 336
  Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment The National Cancer Institute estimates that about ten million Americans...

• Drug Delivery in Cancer - Technologies, Markets and Companies

  EURO€ 3,075.00USD$ 4,000.00GBP£ 2,587.00AUD$ 3,912.00JPY¥ 394,932.00SEK 26 263,00CHF 3'770.00CAD$ 4,076.00 Jain PharmaBiotech, May 2013 , Pages: 669
  Drug delivery remains a challenge in management of cancer Approximately 12 5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery...

• Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 65
  Metastatic Adenocarcinoma of The Pancreas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013', provides an overview of...

• Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 69
  Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013',...

• Soft Tissue Sarcoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 220
  Soft Tissue Sarcoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Soft Tissue Sarcoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 44
  Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2013', provides an overview of...

• Metastatic Ovarian Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 43
  Metastatic Ovarian Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metastatic Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

• Oropharyngeal Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 38
  Oropharyngeal Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Oropharyngeal Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Thymus Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 37
  Thymus Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Thymus Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Uterine Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 308
  Uterine Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Uterine Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Neuroendocrine Tumors - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 79
  Neuroendocrine Tumors – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neuroendocrine Tumors - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 47
  B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Burkitt Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 36
  Burkitt Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Burkitt Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 109
  Waldenstrom Macroglobulinemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 138
  Cutaneous T-Cell Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Indolent Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 100
  Indolent Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Osteosarcoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 74
  Osteosarcoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Metastatic Lung Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 38
  'Metastatic Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Metastatic Lung...

• EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Apr 2013 , Pages: 43
  EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022 Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth of...

• Breast Cancer - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Apr 2013 , Pages: 524
  Breast Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Breast Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• T-Cell Lymphomas - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 222
  T-Cell Lymphomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'T-Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Sarcomas - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 292
  Sarcomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Sarcomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 69
  Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Ovarian Cancer - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Apr 2013 , Pages: 329
  Ovarian Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Squamous Cell Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 213
  Squamous Cell Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Squamous Cell Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 492
  Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Lung Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 544
  Lung Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Glioma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 568
  Glioma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Apr 2013 , Pages: 88
  GBI Research, the leading business intelligence provider, has released its latest research, ""Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars...

• Molecular Diagnostics in Cancer Testing

  EURO€ 2,613.00USD$ 3,400.00GBP£ 2,199.00AUD$ 3,325.00JPY¥ 335,692.00SEK 22 324,00CHF 3'205.00CAD$ 3,465.00 TriMark Publications, Apr 2013 , Pages: 240
  Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added The technologies that come under the umbrella of molecular...

• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Mar 2013 , Pages: 115
  GBI Research, the leading business intelligence provider, has released its latest research “Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival,...

• EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Mar 2013 , Pages: 73
  EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022 Lung cancer is a disease of uncontrolled cell growth in the lung tissues It is one of the most commonly occurring cancers...

• Bone Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 162
  Bone Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Bone Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Non-Hodgkin Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 493
  Non-Hodgkin Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Non-Hodgkin Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Colon Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 43
  Colon Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Colon Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Chronic Back Pain - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 55
  Chronic Back Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Back Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Nonhematologic Malignancy - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 35
  Nonhematologic Malignancy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Chemotherapy Induced Anemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 53
  Chemotherapy Induced Anemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Overactive Bladder - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 132
  Overactive Bladder – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 157
  Graft Versus Host Disease (GVHD) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Diabetes - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 359
  Diabetes – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Diabetes - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...